Clinical Trials Brief | August 24, 2026
This week: the MHRA publishing its route to 14-day reviews for low-risk Phase 1 trials, the White House nominating Heidi Overton as FDA commissioner after three months of acting leadership, the EU approving teclistamab plus daratumumab from second-line myeloma, Ervebo doses being released for use outside the Bundibugyo trial as well as inside it, and an independent data monitoring committee ending AstraZeneca's eVOLVE-Lung02 for futility.
The MHRA publishes its route to 14-day reviews for low-risk Phase 1 trials, competing directly for early-phase work
What changed
On August 17, 2026, the MHRA published guidance on its Phase 1 14-Day Pilot Programme, launched at the end of March 2026. The programme reduces the first cycle of MHRA review for qualifying applications from the standard 30 days to 14 days over the course of 2026. It is restricted to Phase 1 trials in healthy adult volunteers in the UK. According to the LexisNexis summary, first-in-human trials, advanced therapy products, trials involving medical devices or companion diagnostics, and applications that need referral to the Expert Advisory Group or the Commission on Human Medicines are excluded. The timeline steps down from 28 calendar days from March 30 to 14 days from December 28, 2026, with capacity rising to up to four pilot applications per week by the fourth quarter. Sponsors must self-assess eligibility, book a slot and include an eligibility table with the submission.
Why it matters
This is the UK's practical answer to the same competition that drove HHS's Operation TrialBlazer in June and China's fast early-phase approvals: speed of Phase 1 start-up. The scope is narrow because first-in-human studies, the most strategically valuable early trials, are excluded, so in my reading the pilot mainly serves follow-on healthy-volunteer work such as drug-interaction and food-effect studies. The slot-booking model is also notable. It turns regulatory review into a scheduled service with limited capacity, which rewards sponsors who plan submissions precisely and penalises late or incomplete dossiers.
Takeaway
Clinical pharmacology teams placing healthy-volunteer studies in Europe for 2027 should compare the UK's 14-day target against EU timelines under FAST-EU and the US. To use the pilot, dossiers have to be submission-ready on the booked date, because validation within one business day starts the clock.
Sources
This item is grounded in MHRA guidance published August 17, 2026 and the LexisNexis summary of the same day.
The White House nominates Heidi Overton as FDA commissioner after three months of acting leadership
What changed
On August 19, 2026, President Trump announced that he would nominate Heidi Overton, MD, PhD, as commissioner of food and drugs. Overton is deputy director of the White House Domestic Policy Council. According to AABB, she was previously chief policy officer at the America First Policy Institute and served as a White House fellow during the first Trump administration. The nomination requires Senate confirmation. If confirmed, she would replace Marty Makary, who resigned in May; Kyle Diamantas has served as acting commissioner since then. ABC News reported that Diamantas was offered the permanent role several times and declined. HHS Secretary Robert F. Kennedy Jr. publicly endorsed the nomination, and Al Jazeera also reported criticism of the nomination.
Why it matters
This brief has covered a run of consequential FDA decisions made under acting leadership: Operation TrialBlazer, the revised substantial-evidence draft, the mRNA flu vaccine approval and the RP1 approval over its review team's recommendation. A confirmed commissioner shapes how those initiatives are finalised, how guidance comment periods close, and how much weight advisory committees and review divisions carry. The confirmation process will also indicate how far the agency's current direction has political support beyond HHS. Readers should look to Overton's testimony at her confirmation hearing for her stated priorities, rather than infer them from her prior roles.
Takeaway
Sponsors with pending comments on the substantial-evidence draft (due September 22) or the Expedited-IND pilot should assume policy continuity until a confirmed commissioner says otherwise, but should watch the confirmation hearing for positions on single-trial approvals, advisory committees and accelerated approval.
Sources
This item is grounded in reporting by AABB, ABC News and Al Jazeera on August 19, 2026.
The EU approves teclistamab plus daratumumab from second-line myeloma, moving a bispecific into earlier treatment
What changed
On August 21, 2026, Johnson & Johnson announced that the European Commission had approved an extension of indication for Tecvayli (teclistamab) in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. Teclistamab is a BCMAxCD3 bispecific antibody that was first approved in the EU in August 2022 for patients after at least three prior therapies. The approval rests on the Phase 3 MajesTEC-3 trial, which compared subcutaneous teclistamab plus daratumumab with investigator's choice of daratumumab and dexamethasone plus pomalidomide or bortezomib in patients with one to three prior lines. Pharmaceutical Technology reports 291 patients on the combination and 296 on the comparator. The International Myeloma Foundation reported an 83.4% reduction in the risk of progression or death and improved overall survival. CHMP's positive opinion came in June 2026, and FDA approved the combination in March 2026.
Why it matters
Together with FDA's MRD-based approval of iberdomide covered in last week's issue, this shows how fast the myeloma standard of care is changing in the relapsed setting. That has direct consequences for trial design. Control arms built around daratumumab plus a proteasome inhibitor or immunomodulator may stop reflecting EU and US practice in second line, and patients who would have been eligible for current trials will increasingly arrive already exposed to a BCMA-directed bispecific. J&J describes the regimen as steroid-sparing, which also matters for trials that measure quality of life or infection outcomes.
Takeaway
Myeloma sponsors should review comparator arms and prior-therapy eligibility criteria in ongoing and planned second-line trials against the new EU and US labels. Prior BCMA bispecific exposure is becoming a stratification factor and an eligibility question in its own right.
Sources
This item is grounded in Johnson & Johnson's announcement of August 21, 2026 and reporting by CancerNetwork, Pharmaceutical Technology and the International Myeloma Foundation.
Ervebo doses are released for frontline workers outside the Bundibugyo trial as well as for the trial itself
What changed
On August 20, 2026, WHO announced that the Democratic Republic of the Congo will receive 70,000 doses of Ervebo from the global Ebola vaccine stockpile through the International Coordinating Group on Vaccine Provision, after a government request the week before. Of these, 20,000 doses are for a Phase 3 trial to assess whether the vaccine protects against Bundibugyo virus, and 50,000 are for health and frontline workers, following recommendations from WHO's Strategic Advisory Group of Experts on Immunization. Ervebo is licensed against Zaire ebolavirus, and WHO stressed that it is not known whether it works against Bundibugyo. According to WAM, severe side effects from Ervebo have been very rare in clinical trials. Anadolu Agency, citing the DRC Health Ministry, reported 5,208 confirmed infections and 2,476 deaths, making this the deadliest outbreak in the country's history.
Why it matters
Last week's issue covered the plan to test Ervebo in a randomised trial. This week's decision adds a parallel use outside the trial, so the same product will be studied under controlled conditions and used in programmatic settings at the same time. For safety surveillance, that means adverse events in the 50,000 frontline recipients will come through routine pharmacovigilance, not trial reporting, in a conflict-affected region with limited systems. For the trial, in my reading, widespread vaccination of health workers could complicate interpretation if exposure patterns differ between trial participants and vaccinated workers. These are deliberate public-health trade-offs in a fast-growing outbreak, not errors, but they shape what the evidence will be able to show.
Takeaway
Teams supporting the response should make sure that vaccination status, including vaccination outside the trial, is recorded consistently in trial screening and in treatment and prophylaxis studies such as PARTNERS and EBO-PEP. Active safety follow-up for frontline recipients, rather than relying only on spontaneous reports, would make the programmatic data much more useful.
Sources
This item is grounded in WHO's August 20, 2026 announcement as reported by WAM and Anadolu Agency.
An independent data monitoring committee ends AstraZeneca's eVOLVE-Lung02, a setback for PD-1/CTLA-4 bispecifics in first-line lung cancer
What changed
On August 17, 2026, AstraZeneca announced that it is discontinuing the Phase 3 eVOLVE-Lung02 trial of volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with PD-L1 expression below 50%. The decision followed a planned review by the Independent Data Monitoring Committee, which concluded that the combination was unlikely to meet either dual primary endpoint, progression-free survival or overall survival, in the primary analysis population of patients with PD-L1-negative tumours (below 1%). The safety profile was consistent with the known profiles of the individual medicines, with no new safety signals. According to OncLive, the trial enrolled 895 patients across 25 countries. Volrustomig is a bispecific antibody designed to block PD-1 and CTLA-4 on the same T cell. Its other Phase 3 trials in cervical cancer, head and neck cancer and mesothelioma continue.
Why it matters
This is how a well-run futility stop is supposed to work: a prespecified interim look by an independent committee, a clear decision, and a public statement that separates efficacy from safety. For the field, it is a meaningful negative for the idea that dual checkpoint blockade in one molecule can beat PD-1 plus chemotherapy in PD-L1-negative disease, a population where adding CTLA-4 blockade has been thought most likely to help. For the 895 participants and their sites, it starts a closeout process: treatment transitions, follow-up obligations and data reconciliation across 25 countries.
Takeaway
Futility stops are an operational event as much as a scientific one. Sponsors should have site-closeout, participant-transition and final-data-cleaning plans written before the interim analysis, not after. For PD-L1-negative lung cancer, the comparator to beat remains pembrolizumab plus chemotherapy.
Sources
This item is grounded in AstraZeneca's SEC filing of August 17, 2026 and OncLive reporting.